相关实验视频

Updated: Jul 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

一个"一箭三"的策略,以改善CM-272化膀癌免疫疗法

Ruiqi Liu¹, Jiani Yang², Yaqian Du³

¹Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.

Advanced materials (Deerfield Beach, Fla.)

|December 8, 2023

概括

这项研究引入了一种新的纳米平台 (MIL-53@CM-272) 通过提高氧气水平和减少膀癌的耐药性来克服CM-272免疫疗法的局限性. 该平台协同诱导亡,铁亡和免疫细胞死亡,以改善治疗效果.

科学领域:

纳米医学是一种纳米医学.
癌症免疫疗法癌症免疫疗法
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

免疫检查点阻塞疗法显示有前途,但面临局限性.
CM-272是一种表观遗传抑制剂,诱导免疫细胞死亡 (ICD),但受到缺氧的阻碍.
由HIF-1α驱动的缺氧限制了CM-272在抗PD-1治疗中的有效性.

研究的目的:

开发一种用于CM-272输送的新型纳米平台,以克服缺氧引起的局限性.
通过协同方法来增强CM-272的抗瘤疗效.
为了研究纳米医药,CM-272和免疫治疗在膀癌中的联合作用.

主要方法:

将CM-272装入基于Fe3+的纳米金属有机框架 (MIL-53) 中,以创建MIL-53@CM-272.
利用MIL-53载体在瘤微环境 (TME) 中补偿氧气和减少谷氨.
使用RNA测序 (RNA-seq) 来分析与免疫相关的途径和树突细胞成熟.

主要成果:

MIL-53@CM-272实现了超高的CM-272负载 (56.4%) 和高效的TME响应释放.
该纳米平台促进了H2O2分解为O2,增强了声动疗法并减轻了缺氧.
它有效地降低了谷氨,增强了活性氧物种,并诱导了亡和铁亡,增强了对抗PD-1抗体的敏感性.

结论:

在癌症免疫治疗中,MIL-53@CM-272纳米平台代表了克服CM-272局限性的新战略.
这种方法协同地将纳米医学与CM-272结合起来,诱导亡,铁亡和ICD.
这项研究表明有前途的"一箭三"治疗效果,增强树突细胞成熟和抗瘤免疫力.

关键词:

在CM-272中,CM-272是指CM-272中的一个.在MIL-53中,MIL-53是MIL-53的第一个成员.膀癌:膀癌是一种癌症.缺氧缺氧是指缺氧的情况.免疫疗法免疫疗法

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.